Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore’s S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara

This article was originally published in The Pink Sheet Daily

Executive Summary

The multi-kinase inhibitor might have stalled after S*BIO focused on funding its first two candidates in the clinic, CEO says. The company is still involved in preclinical development.
Advertisement

Related Content

Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors
Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors
S*BIO CEO Jan-Anders Karlsson On Development Success In Singapore: An Interview With PharmAsia News

Topics

Advertisement
UsernamePublicRestriction

Register

PS068498

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel